Measles, a highly contagious viral disease, is a major childhood killer in developing countries, accounting for almost 1 million deaths every year globally. Measles virus normally does not cause a persistent infection, no animal reservoir for measles virus exists, no vector is involved in its spread, only one serotype exists, the virus is antigenically stable and vaccination with the currently used live attenuated vaccines proved to be highly effective in preventing disease. Therefore, theoretically measles should be considered eradicable. This article provides a review of past and current measles vaccination efforts and development and need of new generation experimental measles vaccines.
Inactivated vaccine
In theory, measles should be considered eradicable [1] . Large-scale vaccination against measles started in the 1960s. Children were vaccinated with formalin-or tween-ether inactivated, whole-virus vaccines adjuvated with alum. Although high seroconversion rates were observed (>95%), the virus-neutralizing antibody titers were short-lasting, which necessitated multiple immunizations [2] . Furthermore, upon natural infection with measles virus (MV), children vaccinated with the inactivated vaccine developed enhanced disease, referred to as atypical measles [3, 4] . Atypical measles was characterized by a prolonged high fever, an atypical rash and severe pneumonitis, often requiring hospitalization [3, 5, 6 ]. Abdominal pain, hepatic dysfunction, headache, eosinophilia, pleural effusions, hilar adenopathy and edema were also described [7] . As a result of this apparent immunopathological predisposition, the use of inactivated vaccines was abolished. It took long before the underlying mechanism was elucidated and even today we do not have a full understanding of the postulated immunepathogenesis. One of the first hypotheses was that the disease resulted from a lack of functional antibody against the fusion protein [8] . However, reproduction in macaques suggested that atypical measles rather resulted from previous priming for a MV-specific, but nonprotective T-helper (Th)2 response, leading to a strong anamnestic response following challenge resulting in immune complex formation and a pulmonary hypersensitivity response associated with eosinophilia [9] .
Live attenuated vaccine
Based on the safety and efficacy data obtained in early studies with live attenuated measles virus preparations, vaccination against measles was persued again in the 1970s [10, 11] . The application of live attenuated measles vaccines (LAV) resulted in an impressive decline of measles cases, especially in developed countries [12] . Furthermore, recent data suggests that vaccination against measles also reduces mortality from many other causes [13, 14] . Other merits but also demerits of LAV are listed in BOX 1.
Alternative strategies for vaccine administration
Currently, the first LAV dose is given at an age between 9 and 15 months. At this age maternal antibodies, which interfere with replication of the vaccine virus, have vanished in most children. However, in developing countries, measles frequently occurs at an early age (< 9 months) [15] . Ideally, a measles vaccine should be effective when administered to very young infants in the presence of Expert Rev. Vaccines 1(2), (2002) maternally-derived antibody. In an attempt to overcome vaccine neutralization by pre-existing immunity against MV, LAV has been applied with a dose 100-to 1000-fold higher. However, this led to a poorly understood increased mortality in girls in subsequent years as compared with infants vaccinated with standard titer LAV [16] [17] [18] [19] . The currently used LAV, when parenterally administered, has proven to be quite successful. However, vaccine failures may, at least in part, be attributed to an inadequate vaccine-induced mucosal immunity -the current vaccine protects against measles but not necessarily against MV infection [20] . Vaccination strategies that would allow the induction of adequate mucosal immunity may have advantages in this respect. If this could be combined with the easy, inexpensive and safe administration of a stable vaccine, the efforts to eradicate MV would be considerably facilitated. Besides the development of new generations of MV vaccines, the question has been raised whether it would be feasible to apply the existing LAV via mucosal routes instead of the currently used parenteral routes. This could lead to an improved immune response at the site of virus entry. An additional advantage of this strategy might be a more effective vaccination in the presence of pre-existing MV-neutralizing antibody [21, 22] . For measles vaccines this phenomenon was reported years ago by Okune et al. and Ueda et al. [23, 24] . They found that subcutaneously injected LAV was neutralized in the presence of low levels of neutralizing antibody, whereas LAV inhaled as aerosol was not. Since then, the concept of mucosal vaccination using the current LAV has been studied frequently. Different routes of administration have been explored [25] . Live measles vaccines for inhalation, already tested in thousands of children, usually show higher seroconversion rates than the LAV administered via a percutaneous injection [26] [27] [28] [29] . However, the preparation of the aerosol vaccines requires advanced technologies to ensure their efficacy. Live measles vaccines for oral administration using enteric-coated tablets have been tested in laboratory animals with variable degrees of success putting this approach in arrears [30, 31] .
Despite the fact that ample experience has been obtained with the current LAV via the subcutaneous route, the same preparation but administrated via an alternative route will be considered a new vaccine according to current regulations [32] . Thus, as for new generation vaccine formulations, LAV administered via an alternative route would have to go through a complete process of registration and licensing.
Animal models used in evaluation of experimental vaccines
Over the past decades, several animal models have been used for studying the pathogenesis of measles as well as the evaluation of new vaccine candidates and vaccination strategies. Different rodents including mice [33] , rats [34] , ferrets [35] and hamsters [36] have been used to study aspects of experimental MV-induced encephalitis (EMVIE) as a model for neurologic disease and to study MV antigen-induced immune responses using EMVIE as a read-out for protection. These animal species are not susceptible to infection with wild type MV. However, several MV strains have been adapted for use in rodents, although virus replication is in general only detectable after intracerebral inoculation of very young animals. CBA/N mice, grafted with human PBL, were used to study MV vaccine-induced protection in transfer experiments [37] . It needs no explaining that these animals do not develop measles-like disease.
The most successful rodent model for measles research appeared to be the cotton rat (Sigmodon hispidus) model [38] [39] [40] [41] [42] . Cotton rats can be infected intranasally with LAV and nonculture adapted wild type MV isolates. The interference of preexisting virus neutralizing (VN) antibody with vaccination in cotton rats was addressed by transferring MV-specific antibodies of human-or cotton rat-origin and by vaccination of the offspring from seropositive dams [41, 43, 44] .
From the earliest days of measles vaccine research, primates have been used because of their high susceptibility to MV [45] . Nonhuman primates including marmosets (Saguinus mystax), cynomolgus-and rhesus macaques (Macaca fascicularis and Macaca mulatta, respectively) and baboons (Papio hamadryas and Papio hybridus), proved to be most relevant 
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Inexpensive
Balance immune response Safe in immunocompetent individuals [69] More than 30 years of experience [12] Effective in measles control campaigns [12, 65] Combination vaccine with rubella/mumps
Disadvantages
Less effective at young age [70] Interference with maternal antibody [71] Dependent on cold chain [72] Potential risk in immunocompromised individuals [64] Contraindication during pregnancy [73] Needles required Molecular basis of attenuation is not known
Revertants not excluded
Possible contaminations introduced during production [74, 75] Three components (vaccine, diluent and syringe)
Subclinical measles [76, 77] Second dose required for effective control [78] for measles research [46, 47] [48, 55] . Today, techniques and reagents to study immunological mechanisms in nonhuman primates such as T-cell proliferation assays, methods to detect specific antibody and reagents to measure cytokine production and cytokine producing cells, are to a large extent available.
Conventional mouse-and rat-strains have been used for studying the antigenicity of MV-derived antigens, candidate vaccines and the type of immune response induced by these antigens. However, these studies are complicated by the fact that the type of immune reaction (Th1/Th2-like responses) varies among inbred laboratory animals. Transgenic and knockout mice have been used to study different aspects of MV-specific immune responses. Transgenic mice expressing human major histocompatibility complex (MHC) and CD8 molecules mounted cytotoxic T-lymphocyte (CTL) with similar specificities compared with humans with natural MV infection [56] .
Although the pathogenesis of other morbillivirus infections in several animal species is often quite similar to that of MV infection in humans, models using other animal morbilliviruses, like canine distemper virus (CDV) in ferrets and dogs, are not selected for this review.
New generation vaccines
In the mid1980s the scientific community started working on the development of new generation vaccines. Vaccine effectiveness in children aged 4-5 months or younger and one-dose immunization were part of the new recommendations for MV vaccine development. The development of more efficacious vaccines and vaccination strategies for human and animal virus infections is subject of considerable effort [57] . Here, several approaches to develop a new generation of measles vaccines are addressed. A major theme was related to studies aiming at the induction of both VN antibodies and human lymphocyte antigen (HLA) class I-restricted CTL responses. The latter are considered to play a major role in the clearance of MV [58] -their role in the elimination of MV infected cells during infection is considered essential. To induce CTL or activate memory CTL, MV antigens have to enter the endogenous antigen processing and presentation pathway in an antigen-presenting cell (APC), which generally requires de novo protein synthesis [59] . Certain nonreplicating vaccine formulations however, may allow exogenous protein to enter this pathway. Developments in organic chemistry, biochemistry and molecular biology in the past decades have boosted efforts to formulate new generations of vaccines, which indeed allow the efficient induction of both VN antibodies and HLA class I-restricted CTL responses.
The new generation of candidate measles vaccines include: inactivated virus, live viral vectors, live bacterial vectors, subunit vaccines, synthetic vaccines and nucleic acid vaccines. TABLE 1 provides an enumeration of experimental measles vaccines showing the route of administration, the model and the parameters that were addressed. In addition, it is indicated when the vaccine candidate was tested in the presence of preexisting MV-neutralizing antibodies. Given the diversity of the experimental set-up for instance in terms of immunization dose, number of immunizations, time interval between different immunizations, time interval between immunization and challenge and the kind of challenge infection, it is difficult to venture expressing which vaccine candidate would be the best to take part in future vaccination strategies against measles.
Synthetic vaccines have been shown to be efficient activators of CTL and to induce protective immune responses. However, such vaccines will most likely be unsuitable for vaccination of large populations because they would have to be 'tailor-made'. Epitope vaccines are designed for the individual on the basis of MHC restriction, which might be a stumbling block. Peptides are weak immunogens that will require further immunopotentiation if they are to be effective in vivo. The use of adjuvants may also reduce the amount of purified antigen required for successful immunization, thus making vaccine production more economical and practically feasible. At present the only adjuvants registered for human use are still aluminum hydroxide and aluminum phosphate. Synthetic vaccines would of course have several advantages, such as the option that their effectiveness would not necessarily be hampered by pre-existing immunity against measles, the option to orchestrate the type of immune responses (immunomodulation) and good possibilities to be produced under GMP conditions [60, 61] . Furthermore, they are relatively stable and cheap and sequence variations can easily be implemented whenever required. Although VN antibodies induced by different MV strains are known to be crossreactive, the reductionistic approach of a peptide-based vaccine may lead to mismatch between the vaccine and the wild type MV.
For measles, the only subunit and inactivated candidate vaccines that have been extensively studied are the Quil A-based preparations. MV-ISCOMS based on semipurified Quil A have been shown to induce both strong MV-specific VN antibody, which are long lasting and CMI responses both in the absence and presence of pre-existing VN antibody. These vaccine candidates have been tested in different preclinical models and it would now be interesting to test them for their ability to induce protective immune responses in early life. In addition, because of the history of atypical measles associated with inactivated vaccines it will be necessary to test these Quil A-based preparations in the macaque model for atypical measles.
Another novel vaccination approach which has been studied quite extensively for measles is nucleic acid vaccination (also referred to as DNA vaccination). Plasmid DNA is very stable and the possibility of transdermal delivery, avoiding the use of needles, may improve overall compliance rates. A point of concern with regard to DNA vaccination is the possibility that plasmid DNA integrates into genomic material of the host [62] . Whether or not plasmid DNA integration is a real safety issue remains elusive. The outcomes of different studies listed here are not unambiguous but generally it appears that the DNA measles candidate vaccines can efficiently prime the immune system. Although DNA vaccination against measles does not warrant protection, it may be further potentiated in heterologous primeboost vaccination regimens as has recently been demonstrated in combination with an edible candidate measles vaccine [63] . A completely different approach to induce a broadly reactive immune response, including VN antibody and CTL responses, is the use of bacterial and viral vectors, each with their own advantages and disadvantages. Of this group, recombinant poxviruses have been studied most extensively and currently the most interesting vector is the replication-deficient poxvirus, modified vaccinia virus Ankara (MVA). Due to its application in hundreds of thousands of people as a smallpox vaccine in the end-phase of the eradication of variola virus and studies in immunocompromised laboratory animals, it has developed an impressive efficacy and safety record.
Finally, we may contemplate the global eradication of MV. Although the complete elimination of MV from whole continents was achieved with the currently used LAV, global eradication might demand alternative vaccination strategies, such as those being effective in the presence of maternal antibody and waning vaccine-induced immunity. Since the major burden of measles is in developing countries, the vaccination strategy must be able to overcome major logistical problems. A strategy that is based on two doses, or prime-boost regimens, will probably not be possible in certain areas. An initial immunization that only primes the immune system, which probably prevents severe disease, will be sufficient to reduce mortality and morbidity but may allow the virus to continue to circulate. Optimally, at a very young age, one vaccine dose should induce long-lasting protective immunity that may not require an additional booster later in childhood. Due to the HIV epidemic, which is ongoing in certain target populations, safety in immunocompromised individuals must be guaranteed, although recent data showed no evidence for increased adverse events during a measles vaccination campaign in millions of African children [64, 65] . In this respect inactivated vaccine candidates, such as the Quil A-adjuvanted preparations, which show long-lasting high levels of VN antibody after one dose and the poxvirus vector MVA, which is safe and proved to induce protection in the presence of preexisting VN antibody hold promise [53, 54, 66] . Since one-dose human neonatal vaccines have not been described before, future experiments should address the potential of such vaccine candidates in an immature immune system in the absence or presence of variable amounts of maternal-acquired measles antibody. Furthermore, the safety with regard to atypical measles can now be tested in the macaque model [9] . In addition the effectiveness and safety of this candidate measles vaccine should be addressed in LAV-vaccinated individuals and people that have had measles. Vaccination against measles is a neverending story because if measles is eradicated the human population should stay matched for reintroduction of MV via bioterroristic acts and other morbilliviruses via contacts with infected animals [67, 68] .
Expert opinion
There is a growing opposition against vaccination due to reports and noises about adverse events associated with vaccination. Furthermore, the public support for vaccination against measles may weaken with the disappearance of cases with severe disease. Upon eradication of MV the necessity for continuing vaccination against measles will be even more unclear. Therefore, important issues are to provide the public with information and to keep the total number of vaccinations restricted. Today, the LAV vaccine is available as part of the combination vaccine MMR but if the vaccine will be exchanged for a nonreplicating vaccine, which would result in dismantling the MMR vaccine, vaccine developers will need to work on other vaccine cocktails such as combination with DTP or a recombinant MVA containing multiple foreign genes.
Five-year view
In the next 5 years, no new vaccine against measles will be licensed. There are at this moment some promising candidate vaccines. The focus will be on Quil A-adjuvanted preparations and MVA-MV recombinants, which will be further tested in the preclinical models and subsequently in Phase I/II clinical trials in humans. More effort should be invested into testing these vaccine candidates for their ability to induce protection in early life. After having shown the efficacy of a candidate vaccine in adolescent or adult macaques, in the absence and presence of passively transferred MV neutralizing antibody, the efficacy should also be tested in newborn macaques with true maternal antibody.
Despite global efforts to control measles, a satisfactory level of control has not been reached. Therefore, key players in the fight against measles including the following organizations and/or partnerships: International American Red Cross, The International Federation of Red Cross and Red Crescent Societies, The United Nations (UN) Foundation, Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), United Nations Children's Fund (UNICEF), Pan American Health Organization (PAHO), Global Alliance for Vaccines and Immunization (GAVI), World Health Assembly, World Summit for Children, collectively have appointed strategic milestones for vaccination against measles. Currently, boosting vaccination coverage is attempted through massive 'catch-up', 'keep-up' and 'follow-up' campaigns, of which the effect will be evaluated between 2005-2010, depending on the country/region [112, 113] . Application of this strategy has substantially reduced measles transmission in the industrialized world. For this approach the LAV were selected, postponing questions such as: 'do we need new measles vaccines' or 'can the present vaccine be used more efficiently' [114] . The global health partners will determine, on the basis of regional results (interruption of transmission etc.), whether the goal in vaccination against measles will finally be the achievement of a sustainable reduction of measles mortality, maintaining measles elimination or the global eradication of measles. This decision may be compromised by the fact that the feasibility for global eradication of measles dimishes with time, due to the increasing proportion of the human population that has been vaccinated instead of having experienced natural measles as a child. 
Information resources
Key issues
• Vaccination against measles can and will never be discontinued.
• In order to eliminate endemic circulation of measles virus (MV), a very high (≥95%) level of vaccination coverage should be achieved.
• The current live attenuated vaccine against measles is safe, cheap and effective but alternative application routes may increase effectivity (compliance, seroconversion rate, cold chain maintenance) and safety (injection safety and waste disposal). • In the long run, the current live attenuated vaccine against measles should be replaced by a nonreplicating vaccine.
• A vaccine against measles that is effective when administered at a young age in the presence of MV-specific neutralizing antibody would add significantly to the control of MV.
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